Tenax Therapeutics develops oral levosimendan, a drug candidate for pulmonary hypertension in heart failure with preserved ejection fraction. TENX reports earnings on Wed, Nov 11, 2026. Analyst consensus is Buy, based on the latest ratings from 4 firms (2 buy, 2 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in TENX, 0% of them bullish and 100% bearish.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 11 | Chardan Capital | Downgrade | Hold | |
| Aug 11 | Canaccord Genuity | Maintained | Buy | |
| Aug 11 | Guggenheim | Target lowered | Buy | |
| Aug 11 | Evercore ISI Group | Downgrade | Hold | |
| Jul 28 | Canaccord Genuity | Initiated | Buy |
Whale Options Flow
90DNo whale options trades in TENX in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TENX is in one of them and how their past TENX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered TENX in an article yet. Here's the latest on the wider market.
About Tenax Therapeutics
Tenax Therapeutics is a pharmaceutical company developing drugs for cardiopulmonary conditions. Its main candidate is oral levosimendan, a drug already marketed in other countries for acute heart failure, which it is testing for pulmonary hypertension in heart failure with preserved ejection fraction. No therapy is currently approved for that condition in the United States. The company is based in Chapel Hill, North Carolina, and targets patients with this form of pulmonary hypertension.
- Headquarters
- Chapel Hill, NC